Lameditech Co., Ltd. (CEO Choi Jong-seok) , a laser healthcare specialist, announced on the 7th that it has signed a strategic business agreement (MOU) with Iretech Korea Co., Ltd. (CEO Lee Hyeong-seok), a regenerative medical biomaterials company, for the joint development and commercialization of a next-generation skin booster integrated solution.
Through this agreement, both companies will leverage their respective core technologies to fully enter the dermatological medical device market. Lameditech possesses non-invasive laser drug delivery platform (DDS) technology, while Iretech Korea possesses the capability to develop skin boosters based on skin-derived ECM (extracellular matrix). By integrating these two technologies, the two companies plan to collaborate on developing a new type of skin beauty solution that enhances skin efficacy and delivery, and commercialize it.
Lameditech's DDS technology is a non-invasive drug delivery method that creates microchannels without damaging the skin and delivers active ingredients to the dermal layer. It is known to be more efficient and safer than application or injection methods.
Iretech Korea has been developing a high-functionality skin booster product based on ECM biomaterials, and explains that the product has differentiated characteristics from existing hyaluronic acid-based products in terms of biocompatibility and regenerative effects.
Through this agreement, the two companies plan to cooperate in various areas, including joint product development, technology verification, and establishing domestic and international distribution and sales strategies.
According to market research firm Grand View Research, the global skin booster market size is estimated to reach approximately $1.36 billion (KRW 1.8 trillion) in 2024, and the domestic market is growing to approximately KRW 120 billion.
Rameditech and Iretech Korea plan to strengthen their cooperation in product commercialization and distribution targeting the relevant market, and to secure additional revenue models and diversify their business in the skin care medical field in the future.
- See more related articles
You must be logged in to post a comment.